Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it has physiological effects such as glucose-dependent insulin synthesis and secretion, inhibition of β-cell apoptosis, promotion of β-cell proliferation and regeneration, inhibition of glucagon secretion, reduction of food intake, delay of gastric emptying, enhancement of glucose utilization in peripheral tissues and reduction of glycogen output. Liraglutide injection,developed and marketed as Victoza® by Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved by the U.S. Food and Drug Administration in 2010.This 26-week trial compares the effectivity on glycaemic control,safety and immunogenicity of liraglutide injection and Victoza® in patients with type 2 diabetes inadequately controlled by oral metformin alone.

Inclusion Criteria:

• Diagnosed as type 2 diabetes.
• Stably daily dose of metformin alone[between the dose of 1500mg and 2000mg inclusive] for at least 12 weeks prior to day of screening .
• HbA1c(glycosylated haemoglobin) of 7-11%(both inclusive).
• Body mass index (BMI) of 18.5-45 kg/m2(both inclusive).
• The patient must give informed consent to the study before the trial and voluntarily sign the informed consent form.
• The patient can communicate well with the researcher and complete the study in accordance with the research regulations.

Exclusion Criteria:

• Diagnosed as type 1 or other types of diabetes.
• Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, dipeptidyl peptidase-4 (DPP-4) inhibitor and insulin treatment within 3 months before screening.[short term (cumulative use ≤7 days) insulin therapy due to intermittent disease is excluded]
• Treatment with systemic glucocorticoid therapy within 3 months before screening[topical medication or inhaled product is excluded] .
• Treatment with Chinese medicine preparations having hypoglycemic effects within 1 month before screening.
• Patients with recurrent severe or unconscious hypoglycemia within 3 months before screening.
• Patients with acute metabolic complications (ketoacidosis, lactic acidosis or hypertonic coma, etc.) within 6 months before screening.
• History of chronic pancreatitis or idiopathic acute pancreatitis, or suffering from acute or chronic pancreatitis during screening, or blood amylase ≥ 3 times of the upper limit of normal value, or triglycerides ≥ 8.0 mmol / L.
• Fasting blood-glucose(FBG)≥15.0 mmol / L on the day of screening.
• Personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine adenoma (MEN2).
• Patients with obvious liver and kidney dysfunction (alanine aminotransferase (ALT)> 2.5 × upper normal value (ULN), aspartate aminotransferase (AST)> 2.5 ULN, glomerular filtration rate <60 Milliliter(mL) / min / 1.73m2
• Hemoglobin \